All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the MPN Advocates Network.
TRANSLATE
The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by GSK, Novartis, AOP, Sobi and Takeda and supported through independent educational grants from Bristol Myers Squibb, Blueprint Medicines, Incyte and Merck Sharp & Dohme LLC, Rahway, NJ, USA. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View MPN content recommended for you
ASH Congress 2022
14 Feb 2023
#ASH22 | 🎥 The MPN Hub was pleased to speak to @harrisoncn1, Guy’s and St Thomas’ NHS Foundation Trust, London, UK. We asked, Can JAK2V617F VAF variations help predict clinical and survival outcomes?
Watch the full video here 👇
#mpnsm
https://t.co/2fOtmdrJdw
Watch the full video here 👇
#mpnsm
https://t.co/2fOtmdrJdw
10 Feb 2023
#ASH22 | 🎥 The MPN Hub was pleased to speak to Alessandro Vannucchi, @UNI_FIRENZE. We asked, How can chromosomal and mutation abnormalities in chronic MPN inform clinical decision making?
Watch the full video here 👇
#mpnsm
https://t.co/JnU19D0BUE
Watch the full video here 👇
#mpnsm
https://t.co/JnU19D0BUE
6 Feb 2023
#ASH22 | 🎥 The MPN Hub was pleased to speak to John Mascarenhas, Icahn School of Medicine at Mount Sinai, New York, US. We asked, Which patients with MF could benefit the most from telomerase inhibitors?
Watch the full video here 👇
#mpnsm #myelofibrosis
https://t.co/CGtiAfDdsY
Watch the full video here 👇
#mpnsm #myelofibrosis
https://t.co/CGtiAfDdsY
3 Feb 2023
#ASH22 | 🎥 The MPN Hub was pleased to speak to @harrisoncn1, Guy’s and St Thomas’ NHS Foundation Trust, London, UK. We asked, What is the rationale for using BET inhibitors to treat myelofibrosis?
Watch the full video here 👇
#mpnsm #myelofibrosis
https://t.co/IoObe4EPEf
Watch the full video here 👇
#mpnsm #myelofibrosis
https://t.co/IoObe4EPEf
26 Jan 2023
#ASH22 | Are bone marrow fibrosis changes associated with clinical efficacy in patients with myelofibrosis?
Find out in our recent article 👉 https://t.co/5f7OqjFsgD
#MPN #MPNsm
Find out in our recent article 👉 https://t.co/5f7OqjFsgD
#MPN #MPNsm
13 Jan 2023
The MPN Hub summarizes updated results from the MOMENTUM trial presented by @AaronGerds at #ASH22.
Read more here 👇
#MPNsm
https://t.co/RaM6PGILvT
Read more here 👇
#MPNsm
https://t.co/RaM6PGILvT
10 Jan 2023
#ASH22 | Interested in the latest developments in JAK inhibition in #MPN? Read about the latest updates in phase I/II trials from ASH here 👇
#MPNsm
https://t.co/B5V2OTYjDI
#MPNsm
https://t.co/B5V2OTYjDI
5 Jan 2023
#ASH22 | Edimara Reis presented a new anti-CALR mutant monoclonal antibody for the treatment of patients with #MPN. Read more about the discovery and development of this potential new therapy here.
👉 https://t.co/kAZXhj81u5
#MPNsm
👉 https://t.co/kAZXhj81u5
#MPNsm
2 Jan 2023
#ASH22 | 🎥 The MPN Hub was pleased to speak to @harrisoncn1, Guy’s and St Thomas’ NHS Foundation Trust, London, UK. We asked, Can JAK2V617F VAF variations help predict clinical and survival outcomes?
Watch the full video here 👇
#mpnsm
https://t.co/sBVuzqjaU9
Watch the full video here 👇
#mpnsm
https://t.co/sBVuzqjaU9
27 Dec 2022
#ASH22 | 🎥 The MPN Hub was pleased to speak to Alessandro Vannucchi, @UNI_FIRENZE. We asked, How can chromosomal and mutation abnormalities in chronic MPN inform clinical decision making?
Watch the full video here 👇
#mpnsm
https://t.co/G3q1IGyCsr
Watch the full video here 👇
#mpnsm
https://t.co/G3q1IGyCsr
19 Dec 2022
#ASH22 | 🎥 The MPN Hub was pleased to speak to John Mascarenhas, Icahn School of Medicine at Mount Sinai, New York, US. We asked, Which patients with MF could benefit the most from telomerase inhibitors?
Watch the full video here 👇
#mpnsm #myelofibrosis
https://t.co/ShmbIrymTF
Watch the full video here 👇
#mpnsm #myelofibrosis
https://t.co/ShmbIrymTF
15 Dec 2022
#ASH22 | 🎥 The MPN Hub was pleased to speak to @harrisoncn1, Guy’s and St Thomas’ NHS Foundation Trust, London, UK. We asked, What is the rationale for using BET inhibitors to treat myelofibrosis?
Watch the full video here 👇
#mpnsm #myelofibrosis
https://t.co/DtJqDht85B
Watch the full video here 👇
#mpnsm #myelofibrosis
https://t.co/DtJqDht85B
14 Dec 2022
We hope you enjoyed following our live updates and congress coverage from #ASH22!
Keep an eye on our socials for post-congress key points and insights!
#hematology #medicalcongress #cancerresearch #cancerawareness #medicaleducation #mpnsm
Keep an eye on our socials for post-congress key points and insights!
#hematology #medicalcongress #cancerresearch #cancerawareness #medicaleducation #mpnsm
13 Dec 2022
RT @MM_Hub: CONGRESS | #ASH22
@profshanecrotty of the @ljiresearch institute speaks on SARS-CoV-2 and vaccinations in terms of immune respo…
@profshanecrotty of the @ljiresearch institute speaks on SARS-CoV-2 and vaccinations in terms of immune respo…
13 Dec 2022
CONGRESS | #ASH22
Drew Weissman, @WeissmanLab outlines the history of mRNA concluding with the development of the COVID-19 mRNA vaccinations and evaluates the promising future uses of mRNA technology.
Drew Weissman, @WeissmanLab outlines the history of mRNA concluding with the development of the COVID-19 mRNA vaccinations and evaluates the promising future uses of mRNA technology.
13 Dec 2022
#ASH22 | Rosa Ayala @interna_12 presents
BETi BMS-986158 + RUX/FED is reported to have acceptable and manageable safety profiles. BMS-986158 + RUX produced early and deep spleen volume reduction. Enrollment ongoing for RP2D.
#medicalcongress #MPN #MPNsm @ASH22
BETi BMS-986158 + RUX/FED is reported to have acceptable and manageable safety profiles. BMS-986158 + RUX produced early and deep spleen volume reduction. Enrollment ongoing for RP2D.
#medicalcongress #MPN #MPNsm @ASH22
13 Dec 2022
#ASH22 | @mpdrc @MDAndersonNews presents MOMENTUM PRO & HRQoL analyses. Momelotinib provides comprehensive improvements in disease-related symptoms & improved physical function & overall HRQoL vs danazol in MF patients.
#medicalcongress #MPN #MPNsm @ASH22
#medicalcongress #MPN #MPNsm @ASH22
13 Dec 2022
#ASH22 | @jjkiladjian @HopSaintLouis gives an update on the benefit of ropeginterferon alfa-2b in both high & low risk PV patients. The data presented provide further evidence for early treatment start.
#medicalcongress #MPN #MPNsm @ASH22
#medicalcongress #MPN #MPNsm @ASH22
12 Dec 2022
#ASH22| Tiziano Barbui @FromBergamo presents final results from the low-PV phase 2 trial comparing ropeg IFNa2b against ST. 81% of pts on IFNa2b achieved the primary endpoint in year 1 as well as 28% achieving CHR compared to 0% in the standard arm #MPN #MPNsm #medicalcongress
12 Dec 2022
#ASH22| Trine Knudsen, Zealand University Hospital, discusses the results of a QoL and symptom burden assessment during the DALIAH trial for pts treated with ropeg IFNa and HU. At 30 and 36 months post treatment only HU pts had sig increased TSS #MPN #MPNsm #medicalcongress
12 Dec 2022
#ASH22| Steffen Koschmieder @RWTH presents interim analysis of the phase 2b ruxobeat trial comparing RUX against BAT in pts with ET. Treatment with RUX was not superior to BAT in achieving CR but was effective in reducing spleen size and ET symptoms #MPN #MPNsm #medicalcongress
12 Dec 2022
#ASH22| Paola Guglielmelli @UNI_FIRENZE discusses the JAK2V617F molecular response to RUX in pts with PV and ET as well as the association with progression to secondary MF. 18% of pts developed sustained JAK2V617F complete plus deep molecular response #MPN #MPNsm #medicalcongress
12 Dec 2022
#ASH22| Harinder Gill, University of Hong Kong, presents results from a phase 2b sudy investigating bomedemstat for the treatment of ET. 95% of pts achieved a platelet count response ≤400×109/L without new thromboembolic events #MPN #MPNsm #medicalcongress
12 Dec 2022
#ASH22| @DrJosephKim @HopkinsMedicine discusses the group A1 chromatin regulator as a driver of immune evasion through Ag presentation gene repression. He highlights etinostat appears to increase MHC II expression and stimulate an anti-#MPN immune attack. #MPNsm #medicalcongress
12 Dec 2022
#ASH22| Bridget Marcellino @IcahnMountSinai discusses dual targeting of HDM2 and PPM1D as a novel approach for MF. She highlights that PPM1D inhibitors sensitises MF HSPCs to an HDM2 inhibitor and that a novel PPM1D targeting agent is in development #MPN #MPNsm #medicalcongress
12 Dec 2022
#ASH22| @NabihMaslah @univ_paris_cite discusses how JAK inhibition mediates clonal selection of RAS pathway mutations. He highlights unanticipated selection of RAS mutations upon RUX exposure as well as pre treatment screening to avoid clone expansion #MPN #MPNsm #medicalcongress
12 Dec 2022
Keep an eye on our Twitter page!
The @MPN_Hub will be bringing you comprehensive updates as we continue our live coverage of #ASH22.
Session(s) covered today:
- Novel Therapies and Surrogate Endpoints in ET and PV
#hematology #medicalcongress #cancerresearch #mpnsm
The @MPN_Hub will be bringing you comprehensive updates as we continue our live coverage of #ASH22.
Session(s) covered today:
- Novel Therapies and Surrogate Endpoints in ET and PV
#hematology #medicalcongress #cancerresearch #mpnsm
11 Dec 2022
#ASH22| @DrJoeScandura @WeillCornell shows biomarker changes and disease mod in pts with MF treated with pelabresib alone/in combo with RUX. He highlights differences in association of individual markers of disease modification with SVR35 and TSS50 #MPN #MPNsm #medicalcongress
11 Dec 2022
#ASH22| Harinder Gill, University of Hong Kong, discusses the efficacy and safety of ropeg INFa2b for MF pts. CHCR rate was 74% and 67% at wk 12 and 24, while at wk 24 36 of 39 JAK2mut pts had stable or improved allele burden #MPN #MPNsm #medicalcongress
11 Dec 2022
#ASH22| @mpndoc @uwsomwwami gives a talk on pacritinib and the significant anemia benefit it brings for pts with MF. Based on the SIMPLIFY trial criteria 24% of pts on pacritinib achieved transfusion independence compared to 5% on BAT #MPN #MPNsm #medicalcongress
11 Dec 2022
CONGRESS l #ASH22
Srdan Verstovsek from @MDAndersonNews describes that anemia in MF remains a significant challenge, with recurrent transfusions. Momelotinib treatment increases transfusion independence by week 24 (40% vs 19% in other arm), reducing transfusion/treatment burden
Srdan Verstovsek from @MDAndersonNews describes that anemia in MF remains a significant challenge, with recurrent transfusions. Momelotinib treatment increases transfusion independence by week 24 (40% vs 19% in other arm), reducing transfusion/treatment burden
11 Dec 2022
CONGRESS l #ASH22
Srdan Verstovsek from @MDAndersonNews presents evidence from the MOMENTUM clinical trial (NCT04173494), on the role of the JAK-inhibitor momelotinib in patients with MF, with baseline Hb<8 in nearly 50% in both arms
Srdan Verstovsek from @MDAndersonNews presents evidence from the MOMENTUM clinical trial (NCT04173494), on the role of the JAK-inhibitor momelotinib in patients with MF, with baseline Hb<8 in nearly 50% in both arms
11 Dec 2022
#ASH22| @AaronGerds Cleveland Clinic Taussig Cancer Institute presents updated results from the phase 3 Momentum trial investigating momelotinib versus danazol. He highlights sustained TSS responses through week 48 #MPN #MPNsm #medicalcongress
11 Dec 2022
#ASH22| Edimara Reis discusses the discovery of INCA033989, a monoclonal Ab that selectively antagonises CALRmut function in #MPN cells while normalising TPO-R signalling in patient-derived HSPCs. It is currently under therapeutic investigation. #MPNsm #medicalcongress
11 Dec 2022
#ASH22| Benjamin Durham @MSKCancerCenter gives a talk on the use of single agent ERK inhibition to target RAF-independent MEK mutant hystiocytic neoplasms. Results show a promising therapeutic approach and encouraging potential for ulixertinib #MPN #MPNsm #medicalcongress
11 Dec 2022
#ASH22| Fan He @uwsomwwami discusses the prominent role of alpha-ketoglutarate as a novel mediator for platelet activity and monocyte driven inflammation in #MPN, and the subsequent potential for novel therapeutic approaches #MPNsm #medicalcongress
11 Dec 2022
#ASH22| Andrew Perkins @MonashUni discusses germline missense variants in SH2B3 and its association with platelet count variation. He highlights that these variants cause cytoses and influence platelet and leukocyte counts #MPN. #MPNsm #medicalcongress
11 Dec 2022
#ASH22| Rong Li @UniofOxford shows how cross talk between hematopoietic cells and fibroblasts drive inflammation and remodelling of the BM in #MPN, highlighting the cellular subsets EBM and iFib as inflammatory mediators and galactin-1 as a novel biomarker #MPNsm #medicalcongress
11 Dec 2022
#ASH22| @AnnaMarneth @harvardmed gives a talk on how SRSF2mut lowers JAK2 erythrocytosis in mice and is linked with lower Hb in pts with chronic JAK2mut #MPN. She highlights that the data may help identify novel therapeutic targets to reduce anaemia #MPNsm #medicalcongress
11 Dec 2022
#ASH22|Nicole Arellano @Uchicago discusses loss of chaperone function in type 1 calreticulin due to C-terminal structure interference. She highlights structural modelling studies and that CALRins5 mutant has a dominant -ve effect over CALRwt function #MPN #MPNsm #medicalcongress
11 Dec 2022
Keep an eye on our Twitter page!
The @MPN_Hub will be covering the following session(s) today:
- Molecular Consequences of #MPN Driver and Co-mutations
Stay tuned for live updates, key insights, and interview coverage!
#ASH22 #medicalcongress #cancerresearch #MPNSM
The @MPN_Hub will be covering the following session(s) today:
- Molecular Consequences of #MPN Driver and Co-mutations
Stay tuned for live updates, key insights, and interview coverage!
#ASH22 #medicalcongress #cancerresearch #MPNSM
10 Dec 2022
#ASH22|@MPNlab @UCIrvine discusses use of a Mediterranean diet as an intervention for pts with #MPN. She highlights two studies, assessing the ability of pts to adopt the diet through RD counselling as well as the feasibility of online diet intervention #MPNsm #medicalcongress
10 Dec 2022
#ASH22| Marie Kristiansen @UCPH_Research discusses the prevalence of JAK2V617F prevalence in pts with ischaemic stroke. Mutation prevalence in the study was 10.4% in the stroke population and 4.1% in pts over the age of 60 #MPN #MPNsm #medicalcongress
10 Dec 2022
#ASH22| @mpdrc @UTHealthSAMDA presents clinical outcomes of MF pts following immediate transition to momeltoinib from RUX. A rapid improvement in mean Hb and and mean spleen volume was observed, as well as excellent tolerability #MPN #MPNsm #medicalcongress
10 Dec 2022
#ASH22| Paola Guglielmelli @UNI_FIRENZE discusses the molecular characterisation of the response/loss-of-response to RUX in pts with MF. #MPN #MPNsm #medicalcongress
10 Dec 2022
#ASH22| Hélène Pasquer @Institut_IRSL discusses a clinico-molecular arterial and venous thrombotic scoring system for risk startification in #MPN. She highlights key differences in arterial and venous thrombosis and specific risk scores for each entity #MPNsm #medicalcongress
10 Dec 2022
#ASH22| @NicoGagelmann @UKEHamburg discusses TP53 and complex karyotype together as a very high-risk genetic group in MF pts undergoing HSCT. #MPN #MPNsm #medicalcongress
10 Dec 2022
#ASH22| @MosqueraOrgeira @FarmaCHUS discusses machine learning to improve risk stratification in MF. The model achieved high accuracy in predicting overall survival and showed superiority over the IPSS at all time points and age ranges. #MPN #MPNsm #medicalcongress
10 Dec 2022
#ASH22| @mpndoc @SitemanCenter discusses the correlation of BM fibrosis changes and efficacy outcomes in pts with MF. He highlights that anaemia improvement was not found to be linked with BMF changes #MPN #MPNsm #medicalcongress
10 Dec 2022
#ASH22| @FirasElChaer @UVA presents preliminary data from the phase 1/2 trail investigating TP-3654, a Selective Oral PIM1 Kinase Inhibitor for pts with MF. Results shows encouraging spleen volume reduction, symptom improvement, and cytokine reduction #MPN #MPNsm #medicalcongress
10 Dec 2022
#ASH22| @FlorianHeidel Universitätsklinikum Greifswald discusses results from the phase 1/2 ADORE study investigating Siremadlin in combo with RUX for pts with MF. The RP2D was established at 30 mg and resulted in good spleen volume response at wk 24 #MPN #MPNsm #medicalcongress
10 Dec 2022
#ASH22| John Mascarenhas @IcahnMountSinai discusses response durability of pelabresib in combination with RUX for pts with MF. 83% of pts achieved a TSS50 at any point during the study while 40% achieved ≥1 BM fibrosis grade improvement at any time #MPN #MPNsm #medicalcongress
10 Dec 2022
#ASH22| Francesco Passamonti, Circolo Hospital discusses the potential of disease modification with Navitoclax and RUX combination therapy in pts with MF. 50% of pts achieved a JAK2 VAF reduction >20% and 35% of pts a BMF 1-grade improvement.
#MPN #MPNsm #medicalcongress
#MPN #MPNsm #medicalcongress
10 Dec 2022
#ASH22| @AYACOUB7 @Kucancercenter gives a talk on parsaclisib as an add on to RUX therapy in pts with MF. Results show improvement in symptom burden and spleen volume, with daily dosing resulting in better responses compared to daily/weekly regimens. #MPN #MPNsm #medicalcongress
10 Dec 2022
#ASH22| @jjkiladjian @HopSaintLouis presents final results from the Ruxopeg phase 1/2 trial investigating RUX with peg IFNa for pts with MF. He highlights 70% of pts reached the primary study endpoint and was maintained at 12 months post treatment #MPN #MPNsm #medicalcongress
10 Dec 2022
#ASH22| @RaajitRampal @MSKCancerCenter discusses the clinical features of blast phase #MPN and the pathological drivers associated with MPN evolution. He highlights both current and emerging treatment options #MPNsm #medicalcongress
10 Dec 2022
#ASH22| @kristenpettitmd @UMich gives a talk on the phenotypically distinct sub type of 'cytopenic MF'. She highlights clinical features, outcomes, limitations and novel therapeutic strategies associated with this sub type #MPN #MPNsm #medicalcongress
10 Dec 2022
#ASH22| Alessandro Vannucchi @UNI_FIRENZE gives a talk on the common chromosomal and muational abnormalities seen in #MPN and how these inform clinical decisions. He also highlights the use of molecular-integrated risk scoring systems for MF identification #MPNsm #medicalcongress
10 Dec 2022
#ASH22 starts today!
The @MPN_Hub will be covering ASH virtually and in person.
The following session(s) will be covered today:
- JAK/STAT Inhibition and Beyond
Keep an eye on our Twitter page for live updates, key insights, and interview coverage!
#hematology #mpnsm
The @MPN_Hub will be covering ASH virtually and in person.
The following session(s) will be covered today:
- JAK/STAT Inhibition and Beyond
Keep an eye on our Twitter page for live updates, key insights, and interview coverage!
#hematology #mpnsm
30 Nov 2022
Get ready for #ASH22 with us!
The list of top abstracts selected by our steering committee for the 64th @ASH_hematology Annual Meeting and Exposition is now available on the @mpn_hub!
📌 https://t.co/YuCGNwo96W
#ASH2022 #mpnsm #medicalabstracts #cancer #cancerresearch
The list of top abstracts selected by our steering committee for the 64th @ASH_hematology Annual Meeting and Exposition is now available on the @mpn_hub!
📌 https://t.co/YuCGNwo96W
#ASH2022 #mpnsm #medicalabstracts #cancer #cancerresearch
<span> </span>
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Do you include basal serum tryptase (bST) testing in the diagnostic evaluation of patients with MPN?